

Qiang Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5005854/publications.pdf>

Version: 2024-02-01

85
papers

6,612
citations

186265

28
h-index

79698

73
g-index

86
all docs

86
docs citations

86
times ranked

10288
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer challenges worldwide and in China: preparing for the inevitable. <i>Science China Life Sciences</i> , 2022, 65, 442-444.	4.9	10
2	Exogenous H ₂ S reverses high glucose-induced endothelial progenitor cells dysfunction via regulating autophagy. <i>Bioengineered</i> , 2022, 13, 1126-1136.	3.2	5
3	circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer. <i>Molecular Cancer</i> , 2022, 21, 8.	19.2	28
4	Cranial irradiation impairs intrinsic excitability and synaptic plasticity of hippocampal CA1 pyramidal neurons with implications for cognitive function. <i>Neural Regeneration Research</i> , 2022, 17, 2253.	3.0	5
5	Abstract P5-18-10: Mcapegfilgrastim for primary prophylaxis of neutropenia in 355 HER2+ breast cancer patients treated with neoadjuvant docetaxel in combination with trastuzumab and/or pyrotinib: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study. <i>Cancer Research</i> , 2022, 82, P5-18-10-P5-18-10.	0.9	0
6	Abstract OT1-12-06: Neoadjuvant pyrotinib versus pertuzumab in combination with trastuzumab and nab-Paclitaxel for patients with HER2-positive early or locally advanced breast cancer (Pyramid): A randomized, multicenter, open-label, phase 2 trial. <i>Cancer Research</i> , 2022, 82, OT1-12-06-OT1-12-06.	0.9	0
7	Abstract P5-18-06: Proactive diarrhea management improved tolerability of pyrotinib in combination with trastuzumab and docetaxel in patients with HER2+ early or locally advanced breast cancer: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study. <i>Cancer Research</i> , 2022, 82, P5-18-06-P5-18-06.	0.9	0
8	Abstract P2-04-01: Overexpressed cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. <i>Cancer Research</i> , 2022, 82, P2-04-01-P2-04-01.	0.9	0
9	Abstract PD8-08: Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study. <i>Cancer Research</i> , 2022, 82, PD8-08-PD8-08.	0.9	6
10	Association between weight change and breast cancer prognosis. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 677-684.	2.5	1
11	A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. <i>Science China Life Sciences</i> , 2022, 65, 2205-2217.	4.9	7
12	Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	33
13	A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1102-1102.	1.6	18
14	Understanding the Global Cancer Statistics 2018: implications for cancer control. <i>Science China Life Sciences</i> , 2021, 64, 1017-1020.	4.9	108
15	Bioinformatics reveal macrophages marker genes signature in breast cancer to predict prognosis. <i>Annals of Medicine</i> , 2021, 53, 1020-1032.	3.8	24
16	Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 687-697.	2.5	21
17	Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 351-360.	10.7	188
18	The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer. <i>Nature Cancer</i> , 2021, 2, 457-473.	13.2	31

#	ARTICLE	IF	CITATIONS
19	Specimen number based diagnostic yields of suspicious axillary lymph nodes in core biopsy in breast cancer: clinical implications from a prospective exploratory study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 2151-2161.	2.0	2
20	Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer. <i>Nature Immunology</i> , 2021, 22, 865-879.	14.5	41
21	Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study. <i>EBioMedicine</i> , 2021, 69, 103460.	6.1	101
22	A new nomogram for predicting the malignant diagnosis of Breast Imaging Reporting and Data System (BI-RADS) ultrasonography category 4A lesions in women with dense breast tissue in the diagnostic setting. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 3005-3017.	2.0	17
23	Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators. <i>JAMA Oncology</i> , 2021, 7, e213428.	7.1	18
24	Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1904-1909.	30.7	65
25	Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 1712-1724.	7.0	76
26	Associations of reproductive factors with breast cancer prognosis and the modifying effects of menopausal status. <i>Cancer Medicine</i> , 2020, 9, 385-393.	2.8	5
27	New Insights into the Dysfunctions of Pericytes and Neurovascular Units in Neurodegenerative Diseases. <i>Neuroscience Bulletin</i> , 2020, 36, 1570-1572.	2.9	2
28	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). <i>Cancer</i> , 2020, 126, 3867-3882.	4.1	15
29	LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. <i>Nature Communications</i> , 2020, 11, 5513.	12.8	116
30	Gamma ray-induced glial activation and neuronal loss occur before the delayed onset of brain necrosis. <i>FASEB Journal</i> , 2020, 34, 13361-13375.	0.5	12
31	Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2020, 25, e1170-e1180.	3.7	6
32	DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. <i>Nature</i> , 2020, 583, 133-138.	27.8	491
33	Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR Cascade. <i>Cell Reports</i> , 2020, 31, 107753.	6.4	52
34	CSCO breast cancer guideline: precise, economical and oriental. <i>Science China Life Sciences</i> , 2020, 63, 1410-1412.	4.9	12
35	Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy. <i>JCO Precision Oncology</i> , 2020, 4, 244-257.	3.0	32
36	Introduction of a multicenter online database for non-metastatic breast cancer in China. <i>Science China Life Sciences</i> , 2020, 63, 1417-1420.	4.9	5

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. , 2020, 8, e000696.		88
38	A novel approach for 21-genes testing associated with prognosis in Chinese patients with ER-positive/HER2-negative breast cancer: A real-world study.. Journal of Clinical Oncology, 2020, 38, e12528-e12528.	1.6	0
39	Treating HR+/HER2 ⁻ breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Research and Treatment, 2019, 177, 549-559.	2.5	29
40	Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer. BMC Cancer, 2019, 19, 541.	2.6	16
41	<p>Does the radiologist need to rescan the breast lesion to validate the final BI-RADS US assessment made on the static images in the diagnostic setting?<p>. Cancer Management and Research, 2019, Volume 11, 4607-4615.	1.9	4
42	Effects of tea consumption and the interactions with lipids on breast cancer survival. Breast Cancer Research and Treatment, 2019, 176, 679-686.	2.5	8
43	Extracellular vesicle-packaged HIF-1 ⁺ -stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nature Cell Biology, 2019, 21, 498-510.	10.3	488
44	Circ-RHOJ.1 regulated myocardial cell proliferation and apoptosis via targeting the miR-124-3p/NRG-1 axis in myocardial ischemia/reperfusion injury. Archives of Medical Science, 2019, 18, 732-745.	0.9	2
45	Joint effects of multiple sleep characteristics on breast cancer progression by menopausal status. Sleep Medicine, 2019, 54, 153-158.	1.6	4
46	Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer.. Journal of Clinical Oncology, 2019, 37, 1066-1066.	1.6	4
47	Patient and Care Delays of Breast Cancer in China. Cancer Research and Treatment, 2019, 51, 1098-1106.	3.0	23
48	A prognostic 10-miRNA risk score (10-miRNA RS) in predicting neoadjuvant chemotherapy sensitivity of luminal breast cancer.. Journal of Clinical Oncology, 2019, 37, 3139-3139.	1.6	0
49	Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. Nature Communications, 2018, 9, 1595.	12.8	89
50	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nature Communications, 2018, 9, 1614.	12.8	76
51	CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell, 2018, 172, 841-856.e16.	28.9	831
52	Does patient age affect the PPV3 of ACR BI-RADS Ultrasound categories 4 and 5 in the diagnostic setting?. European Radiology, 2018, 28, 2492-2498.	4.5	16
53	Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell, 2018, 175, 442-457.e23.	28.9	198
54	NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nature Immunology, 2018, 19, 1112-1125.	14.5	337

#	ARTICLE	IF	CITATIONS
55	Role of statins in preventing cardiac surgery-associated acute kidney injury: an updated meta-analysis of randomized controlled trials. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 475-482.	2.0	20
56	Prognostic impact of 21-gene recurrence score in patients with node negative breast cancer in China.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24255-e24255.	1.6	0
57	<i>ERBB2</i> mutation profiling with next-generation sequencing (NGS) in solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24264-e24264.	1.6	0
58	Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population. <i>Cardiovascular Therapeutics</i> , 2017, 35, e12251.	2.5	3
59	Mammary stem cells: angels or demons in mammary gland?. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, 16038.	17.1	13
60	Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2 ⁻ breast cancers by the 2015 st . Gallen consensus classification. <i>BMC Cancer</i> , 2017, 17, 28.	2.6	6
61	Deep sequencing reveals a global reprogramming of lncRNA transcriptome during EMT. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 1703-1713.	4.1	18
62	Blocking the recruitment of naive CD4 ⁺ T cells reverses immunosuppression in breast cancer. <i>Cell Research</i> , 2017, 27, 461-482.	12.0	163
63	Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors. <i>Cancer Research</i> , 2017, 77, 175-186.	0.9	22
64	Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 161-168.	2.5	38
65	Cell Cycle Regulation in Treatment of Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 251-270.	1.6	20
66	Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. <i>World Journal of Gastroenterology</i> , 2017, 23, 516.	3.3	32
67	Conversion of CCL18-recruited naive CD4 ⁺ T cells to tumor-infiltrating regulatory T cells in breast cancer and suppression of antitumor immunity.. <i>Journal of Clinical Oncology</i> , 2017, 35, 114-114.	1.6	0
68	Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study. <i>Anticancer Research</i> , 2017, 37, 4539-4547.	1.1	2
69	The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. <i>Oncotarget</i> , 2016, 7, 24848-24859.	1.8	40
70	Noncoding RNAs in Cancer Immunology. <i>Advances in Experimental Medicine and Biology</i> , 2016, 927, 243-264.	1.6	5
71	Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>EBioMedicine</i> , 2016, 11, 199-209.	6.1	43
72	Impact of estrogen receptor- β expression on breast cancer prognosis: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 149-162.	2.5	22

#	ARTICLE	IF	CITATIONS
73	The prognostic value of age for invasive lobular breast cancer depending on estrogen receptor and progesterone receptor-defined subtypes: A NCDB analysis. <i>Oncotarget</i> , 2016, 7, 6063-6073.	1.8	9
74	Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 532-532.	1.6	0
75	Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-11.	1.2	15
76	A Cytoplasmic NF- κ B Interacting Long Noncoding RNA Blocks κ B Phosphorylation and Suppresses Breast Cancer Metastasis. <i>Cancer Cell</i> , 2015, 27, 370-381.	16.8	794
77	miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. <i>Nature Communications</i> , 2015, 6, 8523.	12.8	203
78	E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. <i>Oncotarget</i> , 2015, 6, 31944-31957.	1.8	62
79	Estrogen receptor-beta expression and outcomes in breast cancer: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22056-e22056.	1.6	0
80	Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages. <i>Oncolmmunology</i> , 2014, 3, e953418.	4.6	22
81	A Positive Feedback Loop between Mesenchymal-like Cancer Cells and Macrophages Is Essential to Breast Cancer Metastasis. <i>Cancer Cell</i> , 2014, 25, 605-620.	16.8	607
82	BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10. <i>Nature Communications</i> , 2014, 5, 5406.	12.8	84
83	Overexpression of PITPNM3 promotes hepatocellular carcinoma cell metastasis. <i>Science Bulletin</i> , 2014, 59, 1326-1333.	1.7	3
84	Lin28 Induces Epithelial-to-Mesenchymal Transition and Stemness via Downregulation of Let-7a in Breast Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e83083.	2.5	70
85	CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3. <i>Cancer Cell</i> , 2011, 19, 541-555.	16.8	530